Page 4 - Sarah Sheikh News Today : Breaking News, Live Updates & Top Stories | Vimarsana

AcuraStem Enters into a License Agreement with Takeda to Advance PIKFYVE Therapeutics

/PRNewswire/ AcuraStem, a patient-based biotechnology company pioneering how treatments are developed for neurodegenerative diseases, announced today that.

Prnewswire acurastemSam alworthJustin ichidaQing liuSarah sheikhFoley hoagStevens centerAlzheimer associationDepartment of defenseRainwater charitable foundationHarrington discovery instituteNational institute of neurological disordersAlzheimer drug discovery foundationAmyotrophic lateral sclerosisFrontotemporal dementiaHungs t

Narcolepsy Drug Candidate Promising But Raises Liver Concerns

In narcolepsy patients, TAK-994 showed significant improvements in wakefulness and reduced cataplexy rates but had hepatotoxic effects.

Yves dauvilliersSarah sheikhWake disorders centerNew england journalSleep wake disorders centerGui de chauliac hospitalWakefulness testEpworth sleepiness scaleEpworth sleepiness

The New England Journal of Medicine Publishes Data from Phase 2 Study of First Oral Orexin Receptor 2 Agonist TAK-994 in Patients with Narcolepsy Type 1

The New England Journal of Medicine Publishes Data from Phase 2 Study of First Oral Orexin Receptor 2 Agonist TAK-994 in Patients with Narcolepsy Type 1
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesYuko yoneyamaYves dauvilliersChris stammSarah sheikhTakeda pharmaceutical company limitedProgram terminated for further developmentDepartment of neurologyTakeda pharmaceutical companyWake disorders centerInternational mediaExchange commissionTrial was stopped dueNarcolepsy typeOral orexin receptorDaytime wakefulness

The New England Journal of Medicine Publishes Data from Phase 2 Study of First Oral Orexin Receptor 2 Agonist TAK-994 in Patients with Narcolepsy Type 1

Trial Was Stopped Due to Hepatotoxicity and Consequently TAK-994 Program Terminated for Further Development In Patients with Narcolepsy Type 1, Oral Orexin Receptor 2 Agonist Demonstrated.

United statesSarah sheikhYves dauvilliersWake disorders centerExchange commissionTakeda pharmaceutical company limitedDepartment of neurologyNew england journalOrexin receptorNarcolepsy typeSleep wake disorders centerGui de chauliac hospitalWakefulness testEpworth sleepiness scaleEfficacy resultsNeuroscience therapeutic area unit

Conference on Diplomacy for Development call for boosting US-Pakistan economic ties

Conference on Diplomacy for Development call for boosting US-Pakistan economic ties
dailytimes.com.pk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailytimes.com.pk Daily Mail and Mail on Sunday newspapers.

United statesGilgit baltistanNorthern areasFarhan shabbirMehnaz zaidiMuhammad saeed sheikhIlyas baigIlyas chaudhryNasruddin rupaniMaryam khanSarah sheikhTanvir ahmedElizabeth horstMasood khanMohsin siddiquiInternational academy of letters united states